Search Result

Results for "

Remdesivir

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) DNA/RNA Synthesis (12) Drug Metabolite (5) HCV (5) HCV Protease (3) Influenza Virus (1) Isotope-Labeled Compounds (2) RSV (3) SARS-CoV (16)
By Research Areas:	Infection (19)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-104077

*Remdesivir* Maximum Cited Publications 145 Publications Verification GS-5734	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC₅₀s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for SARS-CoV-2 and its variants alpha, beta, gamma and delta, respectively. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro .

HY-44358

Remdesivir nucleoside monophosphate 2 Publications Verification	DNA/RNA Synthesis SARS-CoV Drug Metabolite	Infection
Remdesivir nucleoside monophosphate is a metabolite of Remdesivir . Remdesivir is a nucleoside analogue with effective antiviral activity against SARS-CoV and MERS-CoV .

HY-131233

Anti-virus agent 1 Remdesivir isopropyl ester analog	Antibiotic	Infection
Anti-virus agent 1 (compound 4i), a phosphoramidate proagent of GS-5734 (HY-104077; Remdesivir), has potent antiviral activity. Anti-virus agent 1 is used for the research of coronavirus and Ebola virus (EBOV) .

HY-136597

Remdesivir O-desphosphate acetonide impurity 2 Publications Verification	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir O-desphosphate acetonide impurity is an impurity of Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity and is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro .

HY-126303

GS-443902 GS-441524 triphosphate; Remdesivir metabolite	DNA/RNA Synthesis SARS-CoV RSV HCV Drug Metabolite	Infection
GS-443902 (GS-441524 triphosphate) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC₅₀s of 1.1 µM, 5 µM for RSV RdRp and HCV RdRp, respectively. GS-443902 is the active triphosphate metabolite of Remdesivir .

HY-145949

Remdesivir de(ethylbutyl 2-aminopropanoate)	Drug Metabolite	Infection
Remdesivir de(ethylbutyl 2-aminopropanoate) is an impurity of Remdesivir. Remdesivir, a nucleoside analogue with effective antiviral activity, has EC₅₀s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro .

HY-104077S2

Remdesivir impurity 9-d4	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir impurity 9-d₄ is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].

HY-150679S

Remdesivir-13C6

GS-5734-¹³C₆
Isotope-Labeled Compounds Others

Remdesivir- ¹³C₆ is the ¹³C labeled Remdesivir[1].

Remdesivir-13C6 GS-5734-¹³C₆	Isotope-Labeled Compounds	Others
Remdesivir- ¹³C₆ is the ¹³C labeled Remdesivir[1].

HY-126303C

GS-443902 trisodium 5+ Cited Publications GS-441524 triphosphate trisodium; Remdesivir metabolite trisodium	DNA/RNA Synthesis SARS-CoV RSV HCV Drug Metabolite	Infection
GS-443902 trisodium (GS-441524 triphosphate trisodium) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC₅₀s of 1.1 µM, 5 µM for RSV RdRp and HCV RdRp, respectively. GS-443902 trisodium is the active triphosphate metabolite of Remdesivir (GS-5734) .

HY-104077S

Remdesivir-d5 2 Publications Verification GS-5734-d₅	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir-d₅ is a deuterium labeled Remdesivir. Remdesivir (GS-5734) is a nucleoside analogue, with effective antiviral activity, with EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of 2019-nCoV (COVID-19) infection in vitro[1][2].

HY-104077S1

Remdesivir-d4 GS-5734-d₄	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir-d₄ is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].

HY-151265

MMT5-14	SARS-CoV	Infection
MMT5-14 is a remdesivir analogue with a higher antiviral activity in four variants of SARS-CoV-2 than Remdesivir (HY-104077). MMT5-14 inhibits SARS-CoV-2, α, β, γ and δ variants with EC₅₀s of 0.4, 2.5, 15.9, 1.7 and 5.6 μM, respectively. MMT5-14 can be used for the research of COVID-19 .

HY-133894

Bofutrelvir FB2001	SARS-CoV	Infection
Bofutrelvir (FB2001) is a SARS-CoV-2 main protease M ^pro inhibitor with an IC₅₀ value of 53 nM and an EC₅₀ value of 0.53 μM. Bofutrelvir exhibits potent antiviral efficacy against several current SARS-CoV-2 variants with EC₅₀ values of 0.26-0.42 μM. Bofutrelvir has an additive antiviral effect when combined with Remdesivir (HY-104077) .

HY-161356

BPR3P0128	SARS-CoV	Infection
BPR3P0128 is an orally active, non-nucleoside RNA-dependent RNA polymerase (RdRp) inhibitor that has been shown to inhibit the activity of various SARS-CoV-2 variants. The EC₅₀ for SARS-CoV-2 and HCoV-229E are 0.62 µM and 0.14 µM. BPR3P0128 demonstrates effective anti-pancoronavirus activity within the submicromolar range. PR3P0128 shows synergistic antiviral activity when combined with Remdesivir (HY-104077) .

HY-10241

Simeprevir 35+ Cited Publications TMC435; TMC435350	HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (M ^pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-10241A

Simeprevir sodium TMC435 sodium; TMC435350 sodium	HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir (TMC435; TMC435350) sodium is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir sodium inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir sodium also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir sodium inhibits the main protease (M ^pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-10241S

Simeprevir-13C,d3 TMC435-¹³C,d₃; TMC435350-¹³C,d₃	Isotope-Labeled Compounds HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses[1][2][5].

HY-136303

GS-704277 2 Publications Verification	Drug Metabolite	Infection
GS-704277 is an alanine metabolite of Remdesivir. Remdesivir, a nucleoside analogue with effective antiviral activity, is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro .

HY-103586

GS-441524 15+ Cited Publications	DNA/RNA Synthesis SARS-CoV	Infection
GS-441524, predominant metabolite of Remdesivir and superior to Remdesivir against Covid-19 , shows comparable efficacy in cell-based models of primary human lung and cat cells infected with coronavirus. GS-441524 could strongly inhibits feline infectious peritonitis virus (FIPV), with an EC₅₀ of 0.78 μM .

HY-145119AS

Mindeudesivir hydrobromide JT001; VV116; GS-621763-d₁ hydrobromide	SARS-CoV RSV Influenza Virus	Infection
Mindeudesivir (JT001; VV116; GS-621763-d₁) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19 .

Cat. No.	Product Name	Chemical Structure

HY-104077S

Remdesivir-d5 2 Publications Verification
Remdesivir-d₅ is a deuterium labeled Remdesivir. Remdesivir (GS-5734) is a nucleoside analogue, with effective antiviral activity, with EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of 2019-nCoV (COVID-19) infection in vitro[1][2].

HY-104077S2

Remdesivir impurity 9-d4
Remdesivir impurity 9-d₄ is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].

HY-150679S

Remdesivir-13C6

Remdesivir- ¹³C₆ is the ¹³C labeled Remdesivir[1].

Remdesivir-13C6
Remdesivir- ¹³C₆ is the ¹³C labeled Remdesivir[1].

HY-104077S1

Remdesivir-d4
Remdesivir-d₄ is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].

HY-10241S

Simeprevir-13C,d3
Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses[1][2][5].

Simeprevir-13C,d3

Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses[1][2][5].

HY-145119AS

Mindeudesivir hydrobromide
Mindeudesivir (JT001; VV116; GS-621763-d₁) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19 .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.